SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-22-050669
Filing Date
2022-08-24
Accepted
2022-08-24 10:30:30
Documents
36
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea164763-6k_xtlbio.htm   iXBRL 6-K 71892
2 CONDENSED INTERIM UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS ea164763ex99-1_xtlbio.htm   iXBRL EX-99.1 238529
  Complete submission text file 0001213900-22-050669.txt   1530750

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE xtlb-20220630.xsd EX-101.SCH 31522
4 XBRL CALCULATION FILE xtlb-20220630_cal.xml EX-101.CAL 19713
5 XBRL DEFINITION FILE xtlb-20220630_def.xml EX-101.DEF 79971
6 XBRL LABEL FILE xtlb-20220630_lab.xml EX-101.LAB 185208
7 XBRL PRESENTATION FILE xtlb-20220630_pre.xml EX-101.PRE 86117
30 EXTRACTED XBRL INSTANCE DOCUMENT ea164763-6k_xtlbio_htm.xml XML 142193
Mailing Address 5 HACHAROSHET ST. RAANANA L3 4365603
Business Address XTL BIOPHARMACEUTICALS LTD C/O ALSTON & BIRD LLP, 90 PARK AVENUE NEW YORK NY 10016 972 9 955 7080
XTL BIOPHARMACEUTICALS LTD (Filer) CIK: 0001023549 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3
Type: 6-K | Act: 34 | File No.: 001-36000 | Film No.: 221189397
SIC: 2834 Pharmaceutical Preparations